Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Summary

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.

Timeline

Start

2024-07-16

Primary completion

2027-09-28

Completion

2028-03-24

Drugs

Indications